{"nctId":"NCT00168103","briefTitle":"Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks","startDateStruct":{"date":"2005-06"},"conditions":["Hereditary Angioedema"],"count":126,"armGroups":[{"label":"C1-INH 10 U/kg bw","type":"EXPERIMENTAL","interventionNames":["Biological: C1 Esterase Inhibitor"]},{"label":"C1-INH 20 U/kg bw","type":"EXPERIMENTAL","interventionNames":["Biological: C1 Esterase Inhibitor"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"C1 Esterase Inhibitor","otherNames":["Berinert","Berinert P","CE1145"]},{"name":"Placebo","otherNames":["Physiological saline solution"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Documented congenital C1-INH deficiency\n* Acute facial or abdominal HAE attack\n\nKey Exclusion Criteria:\n\n* Acquired angioedema\n* Treatment with any other investigational drug within the last 30 days before study entry\n* Treatment with any C1-INH concentrate within the previous 7 days","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Start of Relief of Symptoms From HAE Attack","description":"The start of symptom relief was determined by subject self-assessment. Time to start of symptom relief was set to 24 hours if the subject received rescue medication (blinded study medication, narcotic analgesics, antiemetics, open-label C1-INH, or fresh frozen plasma) at any time point after the start of study treatment but before start of relief.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"10.513"},{"groupId":"OG001","value":"0.5","spread":"8.202"},{"groupId":"OG002","value":"1.5","spread":"11.481"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Worsened Intensity of Clinical HAE Symptoms","description":"Includes any worsening of intensity of at least 1 of the HAE symptoms present at baseline. Routinely checked symptoms included pain, nausea, vomiting, cramps, and diarrhea.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Time to Complete Resolution of All HAE Symptoms, Including Pain","description":"Complete resolution of symptoms was determined by subject self-assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.00","spread":"494.230"},{"groupId":"OG001","value":"4.92","spread":"314.347"},{"groupId":"OG002","value":"7.79","spread":"382.815"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Subjects Receiving Rescue Study Medication","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Vomiting Episodes","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.77"},{"groupId":"OG001","value":"0","spread":"0.41"},{"groupId":"OG002","value":"0","spread":"2.59"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":39},"commonTop":["Nausea","Muscle spasms","Abdominal pain","Pain","Diarrhea"]}}}